Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma

Cancer Science

Volumn 101, Issue 1, 2010, Pages 155-160

  Shimada, Keiji ^a   Nakamura, Mitsutoshi ^a   De Velasco, Marco A ^b   Tanaka, Motoyoshi ^b   Ouji, Yukiteru ^c   Miyake, Makito ^a   Fujimoto, Kiyohide ^a   Hirao, Kazuya ^d   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Department of Parasitology ^*  (Japan)

^d Hirao Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; FLICE INHIBITORY PROTEIN; KU ANTIGEN; PROTEIN KU 7; RED FLUORESCENT PROTEIN; SMALL INTERFERING RNA; SYNDECAN 1; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA IN SITU; CELL LABELING; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; UROTHELIAL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; RNA, SMALL INTERFERING; SYNDECAN-1; URINARY BLADDER NEOPLASMS;

EID: 71849097523     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01379.x     Document Type: Article

References (31)

1. Bernfield M, Gotte M, Park PW. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999, 68:729-77.
2. Dhodapkar MV, Abe E, Theus A. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 1998, 91:2679-88.
3. Wijdenes J, Vooijs WC, Clement C. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996, 94:318-23.
4. Mahtouk K, Cremer FW, Reme T. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 2006, 25:7180-91.
5. Derksen PW, Keehnen RM, Evers LM, Van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002, 99:1405-10.
6. Yang Y, MacLeod V, Dai Y. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007, 110:2041-8.
7. Nikolova V, Koo CY, Ibrahim SA. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009, 30:397-407.
8. Shimada K, Nakamura M, Anai S. A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. Cancer Res 2009, 69:3157-64.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70.
10. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev 2005, 5:713-25.
11. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005, 24:5218-25.
12. Mhawech-Fauceglia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 2006, 106:1205-16.
13. Liebert M, Seigne J. Characteristics of invasive bladder cancers: histological and molecular markers. Semin Urol Oncol 1996, 14:62-72.
14. Shimada K, Nakamura M, Ishida E. C-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas. Am J Pathol 2007, 171:1003-12.
15. Shimada K, Nakamura M, Ishida E, Konishi N. Urothelial carcinoma with plasmacytoid variants producing both human chorionic gonadotropin and carbohydrate antigen 19-9. Urology 2006, 68:891-e7.
16. Nigwekar P, Tamboli P, Amin MB, Osunkoya AO, Ben-Dor D, Amin MB. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol 2009, 33:417-24.
17. Shimada K, Nakamura M, Konishi N. A case of urothelial carcinoma with triple variants featuring nested, plasmacytoid, and lipoid cell morphology. Diagn Cytopathol 2009, 37:272-6.
18. Sabichi A, Keyhani A, Tanaka N. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol 2006, 175:1133-7.
19. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J Pathol 2005, 206:423-32.
20. Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E, Shimada K. Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol 2002, 160:1207-14.
21. De Velasco MA, Tanaka M, Anai S, Tomioka A, Nishio K, Uemura H. GFP image analysis in the mouse orthotopic bladder cancer model. Oncol Rep 2008, 20:543-7.
22. Su G, Blaine SA, Qiao D, Friedl A. Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res 2008, 68:9558-65.
23. Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 2009, 206:691-705.
24. Day TW, Huang S, Safa AR. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol 2008, 76:1694-704.
25. Irmler M, Thome M, Hahne M. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-5.
26. Kataoka T, Budd RC, Holler N. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 2000, 10:640-8.
27. Shimada K, Nakamura M, Matsuyoshi S, Ishida E, Konishi N. Specific positive and negative effects of FLIP on cell survival in human prostate cancer. Carcinogenesis 2006, 27:1349-57.
28. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-400.
29. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002, 4:E131-6.
30. Li W, Zhang X, Olumi AF. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res 2007, 67:2247-55.
31. Sauter G, Moch H, Mihatsch MJ, Gasser TC. Molecular cytogenetics of bladder cancer progression. Eur Urol 1998, 33(Suppl 4):9-10.